Co-ordinated overexpression of SIRT1 and STAT3 is associated with poor survival outcome in gastric cancer patients

Oncotarget

Volumn 8, Issue 12, 2017, Pages 18848-18860

  Zhang, Shu ^a,b   Huang, Shuling ^a,b   Deng, Chao ^a,b,c   Cao, Yu ^a,b   Yang, Jun ^a   Chen, Guangxia ^d   Zhang, Bin ^a,b   Duan, Chaoqin ^a,b   Shi, Jiong ^a   Kong, Bo ^a,e   Friess, Helmut ^e   Zhao, Nanyi ^f   Huang, Chen ^g   Huang, Xiaoli ^h   Wang, Lei ^a,b   Zou, Xiao Ping ^a,b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b Jiangsu Clinical Medical Center of Digestive Disease   (China)

^c Department of Ophthalmology   (China)

^d First People's Hospital of Xuzhou   (China)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g FUWAI HOSPITAL   (China)

^h Department of Gastroenterology   (China)

Author keywords

Gastric cancer; Prognosis; SIRT1; STAT3

Indexed keywords

SIRTUIN 1; SIRTUIN 2; STAT3 PROTEIN; SIRT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; STOMACH CANCER; SURVIVAL TIME; TUMOR VOLUME; UPREGULATION; BIOSYNTHESIS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SIRTUIN 1; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS;

EID: 85015747397     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14473     Document Type: Article

References (25)

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng, Hongmei1. Cancer Statistics in China, 2015. CA Cancer J Clin 00 1-18 (2016). Cancer Statistics in China, 2015. CA Cancer J Clin. 2016; 00:1-18. doi: 10.3322/caac.21338.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015; 65:87-108. doi: 10.3322/caac.21262.
3. Huang Q, Fang C, Shi J, Sun Q, Wu H, Gold JS, Weber HC, Guan W, Zhang Y, Yu C, Zou X, Mashimo H. Differences in Clinicopathology of Early Gastric Carcinoma between Proximal and Distal Location in 438 Chinese Patients. Sci Rep [Internet]. Nature Publishing Group; 2015; 5:13439. doi: 10.1038/srep13439.
4. Valenzuela MA. Helicobacter pylori-induced inflammation and epigenetic changes during gastric carcinogenesis. World J Gastroenterol. 2015; 21:12742. doi: 10.3748/wjg.v21. i45.12742.
5. Yang T-C, Hou M-C, Chen P-H, Hsin I-F, Chen L-K, Tsou M-Y, Lin H-C, Lee F-Y. Clinical Outcomes and Complications of Endoscopic Submucosal Dissection for Superficial Gastric Neoplasms in the Elderly. Medicine (Baltimore). 2015; 94:e1964. doi: 10.1097/MD.0000000000001964.
6. Bartosch C, Monteiro-reis S, Almeida-rios D, Vieira R. Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium. Oncotarget. 2016; 7: 1144-54. doi: 10.18632/oncotarget.6691.
7. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park B-H, Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, Moon WS, Jang KY. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res. 2009; 15:4453-9. doi: 10.1158/1078-0432.CCR-08-3329.
8. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer. 2009; 9:123-8. doi: 10.1038/nrc2562.
9. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, Koh DH, Moon WS, Jang KY. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol. 2011; 42:204-13. doi: 10.1016/j.humpath.2010.05.023.
10. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, Nagy TR. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007; 67:6612-8. doi: 10.1158/0008-5472.CAN-07-0085.
11. Wang H, Liu H, Chen K, Xiao J, He K, Zhang J, Xiang G. SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling. Oncol Rep. 2012; 28:311-8. doi: 10.3892/or.2012.1788.
12. Wen YC, Wang DH, RayWhay CY, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005; 123:437-48. doi: 10.1016/j.cell.2005.08.011.
13. Yang Q, Wang B, Gao W, Huang S, Liu Z, Li W, Jia J. SIRT1 is downregulated in gastric cancer and leads to G1-phase arrest via NF-kappaB/Cyclin D1 signaling. Mol Cancer Res. 2013; 11:1497-507. doi: 10.1158/1541-7786. MCR-13-0214.
14. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SHL, Watkins DN, Herman JG, Baylin SB. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006; 2:0344-52. doi: 10.1371/journal.pgen.0020040.
15. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Jia R, Zheng ZM, Appella E, et al. Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice. Cancer Cell. 2008; 14:312-23. doi: 10.1016/j. ccr.2008.09.001.
16. Kang Y, Jung WY, Lee H, Kim ELA, Kim BH. Expression of SIRT1 and DBC1 in gastric adenocarcinoma. Korean J Pathol. 2012; 46:523-31. doi: 10.4132/KoreanJPathol.2012.46.6.523.
17. Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, Horvath TL, Gao Q. STAT3 inhibition of gluconeogenesis is downregulated by SIRT1. Nat Cell Biol. 2009; 11:492-500. doi: 10.1038/ncb1857.
18. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9:798-809. doi: 10.1038/nrc2734.
19. Lu JJ, Zhang LP, Chen X, Lu QM, Yang YX, Liu JP, Ma X. SIRT1 counteracted the activation of STAT3 and NF-κB to repress the gastric cancer growth. Int J Clin Exp Med. 2014; 7:5050-8.
20. Feng AN, Zhang LH, Fan XS, Huang Q, Ye Q, Wu HY, Yang J. Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int J Surg Pathol. 2011; 19:743-50. doi: 10.1177/1066896911412181.
21. Huang S, Chen M, Shen Y, Shen W, Guo H, Gao Q, Zou X. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett. 2012; 315:198-205. doi: 10.1016/j.canlet.2011.10.011.
22. Grbesa I, Pajares MJ, Mart, nez-Terroba E, Agorreta J, Mikecin AM, Larr, yoz M, Idoate MA, Gall-Troselj K, Pio R, Montuenga LM. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One. 2015; 10. doi: 10.1371/journal. pone.0124670.
23. Peters CJ, Rees JRE, Hardwick RH, Hardwick JS, Vowler SL, Ong CJ, Zhang C, Save V, O'Donovan M, Rassl D, Alderson D, Caldas C, Fitzgerald RC. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 2010; 139. doi: 10.1053/j. gastro.2010.05.080.
24. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal [Internet]. 2013; 6:pl1. doi: 10.1126/scisignal.2004088.
25. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401-4. doi: 10.1158/2159-8290.CD-12-0095.